60 abstracts to be presented across broad and growing portfolio of vaccines and medicines aimed at getting ahead of infectious disease
New data to be shared on GSK’s RSV vaccine across different age groups of patients at increased risk
Efficacy data for gepotidacin in patients with a high unmet need suffering from uUTIs to be shared against a backdrop of rising antimicrobial resistance
New evidence to be shared on real-world impact of ViiV Healthcare’s innovative, long-acting HIV prevention and treatment portfolio
GSK plc (LSE/NYSE: GSK) and ViiV Healthcare will share new data from their industry-leading, prevention-focused infectious disease pipeline and portfolio at the Infectious Disease Society of America’s IDWeek 2024 annual meeting in Los Angeles from 16-19 October 2024. 60 abstracts will be presented, showcasing data for vaccines and medicines across a range of infectious diseases including respiratory syncytial virus (RSV), herpes zoster, uncomplicated urinary tract infections (uUTI) and HIV.
Vaccines
22 abstracts from GSK’s vaccines pipeline and portfolio have been accepted, including new data for Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) and Shingrix (Zoster Vaccine Recombinant, Adjuvanted). Presentations on GSK’s RSV vaccine will include data across different age ranges in older adults and post-marketing safety data, plus 10 other abstracts featuring evidence across comorbidities of interest, seasons and geographies. Additional presentations include overviews of GSK's 5-in-1 meningococcal ABCWY vaccine candidate and the risks of invasive meningococcal disease in young children.
Medicines
Among the abstracts from GSK’s infectious disease therapeutics portfolio, 13 abstracts will highlight data for gepotidacin, an investigational, first-in-class oral antibiotic with a novel mechanism of action for uUTI and urogenital gonorrhoea (GC). This includes an oral presentation of clinical data from the EAGLE-2 and EAGLE-3 phase III trials, examining the efficacy of gepotidacin in patient subgroups with uUTIs with a high unmet need in the context of rising antimicrobial resistance (AMR). Additional data on surveillance and the burden of AMR in uUTIs and treatment failure in uUTIs will also be highlighted.
HIV prevention and treatments
Additionally, ViiV Healthcare will present 22 abstracts from its innovative HIV treatment and prevention portfolio. Two oral presentations will share real-world evidence from the OPERA and TRIO studies, evaluating the effectiveness of, adherence to and persistence in the use of Apretude (cabotegravir long-acting (LA)) for HIV pre-exposure prophylaxis (PrEP) across diverse populations.
Findings from the PILLAR study will highlight the impact of cabotegravir LA for PrEP on common challenges associated with daily oral PrEP, such as stigma and anxiety. Additional abstracts highlight ViiV’s industry-leading long-acting and two-drug regimens for the treatment of HIV including treatment benefits, satisfaction and preference, offering new insights for healthcare providers seeking to optimise care to suit individual needs and circumstances.
Tony Wood, Chief Scientific Officer, GSK said: “Infectious diseases represent a major threat to human health, which is why two-thirds of our pipeline focuses on pioneering new technologies to deliver preventative options – like vaccines and HIV PrEP – plus therapeutic solutions. At IDWeek 2024, we’re proud to share data highlighting our scientific developments in the prevention and treatment of diseases like RSV, herpes zoster, uUTI and HIV, while also working to tackle the challenge of antimicrobial resistance.”
For more than 70 years, GSK has been advancing a comprehensive portfolio of medicines and vaccines for infectious diseases. Considerable progress has been made, but there remains significant work to do to address the burden of infectious diseases on individuals, society and healthcare systems:
More than one billion people are infected annually by seasonal respiratory viruses such as influenza and RSV.1,2 People living with certain underlying health conditions are at increased risk of hospitalisation or death due to RSV.3
About 40 million people live with HIV worldwide, many of whom still face stigma and do not have adequate access to care.4
AMR threatens to undermine the progress that has been made to date and prevent further gains. Without action, AMR could contribute to 40 million deaths by 2050.5
In support of its ambition to get ahead of disease, GSK continues to advance the science, pursuing new solutions while continuing to build the evidence base for its vaccines and treatments. With the breadth of data presented at IDWeek, GSK and ViiV Healthcare highlight their goal to pioneer a new range of first- or best-in-class options to close the gap in prevention and treatment for patients who deserve more.
Full list of GSK and ViiV Healthcare’s presentations at IDWeek 2024:
Abstracts from GSK's Vaccines Portfolio
see & read more on
https://www.gsk.com/en-gb/media/press-releases/gsk-and-viiv-healthcare-to-showcase-advances-across-industry-leading-infectious-disease-portfolio-at-idweek-2024/ |
